Clinical trial / 2017
In a subset of Alzheimer's patients, 52 weeks of resveratrol altered neuro-inflammatory markers and attenuated cognitive and functional decline.
Banked CSF and plasma samples from a subset of 38 biomarker-confirmed Alzheimer's disease subjects randomized to resveratrol (up to 1 g orally twice daily) or placebo for 52 weeks were analyzed. At 52 weeks, resveratrol significantly reduced CSF MMP9 and increased MDC, IL-4, and FGF-2 compared to placebo, while increasing plasma MMP10 and decreasing IL-12P40, IL12P70, and RANTES from baseline. Resveratrol treatment attenuated declines in MMSE scores, ADCS-ADL scores, and CSF Aβ42 levels over 52 weeks, without altering tau levels.
- Study type
- Randomized controlled trial (retrospective subset analysis)
- Who was studied
- 38 individuals with biomarker-confirmed mild-moderate Alzheimer's disease (19 resveratrol, 19 placebo)
- What was measured
- CSF and plasma neurodegenerative/inflammatory markers, MMPs, MMSE, ADCS-ADL, and CSF Abeta42/tau
THE PAPER
Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease.
Moussa C, Hebron M, Huang X, Ahn J, Rissman RA, Aisen PS, Turner RS. J Neuroinflammation, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.